Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Good Morning , interesting research paper on STS . ( courtesy of twitter ) no mention of AVA6000.
"Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy"
"The tumor microenvironment consists of complex cellular com-munities that are essential for tumor development and response to therapies such as ICI14. Unlike most human cancers that arise from epithelial tissues, sarcomas arise from mesenchymal cells, leading to unique interactions with the surrounding stroma. Due to the rarity of STSs, few studies have explored the sarcoma microenvironment at the single-cell level15. Furthermore, most clinical samples are formalin fixed and paraffin embedded (FFPE), leading to nucleic acid crosslinking and preventing single-cell dissociation. As a result, standard approaches to study the tumor microenvironment such as flow cytometry and single-cell RNA sequencing (scRNA-seq) are not feasible in large, clini-cally annotated datasets."
Amazing that Tufts/Avacta have discovered /trialing in clinic a solution using pre|CISION™ technology FAP as a target . Hopefully soon be recognised as a cancer breakthough treatment , maybe after scientific peer reviews we will see news communicated to a wider audience .
https://www.nature.com/articles/s43018-024-00743-y.epdf?sharing_token=LPSI_8LlXlKrZ2UaUpIj0NRgN0jAjWel9jnR3ZoTv0Pa0-vstvN93H39y7XMEMZAYKgrCViG5BfL37psOW5Ng2zLd50LIML93uPEd_mtNaODXcYqYhYbO54zegC7Ki6Dt5q4RmcKn5G6SihOqFqsA0J-TPHBOycvglRfCfR3NqY%3D
Https://avacta.com/investors/proposed-fundraise-to-progress-therapeutics-division-pipeline/
RNS: Proposed Fundraise to progress Therapeutics Division pipeline
RNS: Proposed REX Retail Offer
RNS: Result of Placing
Notice of General Meeting
Notice of General Meeting – Circular
I would imagine any interested external party looking at the potential of Avacta assets will use a more sophisticated valuation method than just the SP . Avacta have employed new people to spread the word .
https://www2.deloitte.com/uk/en/pages/life-sciences-and-healthcare/articles/building-a-biotech-valuation-a-deloitte-perspective.html
Meanwhile Avacta make progress , every day AVA6000 cohorts data outcomes results are added - validating /understanding how the technology best works for cancer patients . Thereby better chance of attracting new partners to help with pre|CISIONTM platform commercialisation . Other JV Therapeutics partners continue as intended . Diagnostics extends its global customer base with proven products , providing cash into company coffers still on the balance sheet .
What is not to like - funding sorted . OK the current SP stinks my paper deficit -55.45% . Leave blame game to others
"Cash at 1 January stood at £16.6m, which was significantly better than consensus expectations and indicates a sharp reduction in the pace of net cash utilisation in 2H23. "
Might be Avacta Diagnostics LD /Coris generating revenues
-------------------------
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,482 followers1,482 followers
6h • 6h •
Launch Diagnostics is the exclusive distributor of Liofilchem products in the UK.
For more information visit:
launchdiagnostics.com
…see more
https://www.launchdiagnostics.com/products/
LiofilchemLiofilchem
8,713 followers8,713 followers
3d • 3d •
Follow
Chromatic Colistin is a selective chromogenic medium used for the isolation and differentiation of Colistin-resistant Gram-negative bacteria.
This medium is intended for screening of faecal samples and can also be used to confirm colistin resistance of isolates from non-selective and non-chromogenic culture media.
IFU: https://lnkd.in/dBSq5BgK
Ref. 11640
20 plates/pack
120 days shelf life
2-8°C storage temperature
http://www.liofilchem.net/login/pd/ifu/11640_IFU.pdf
hashtag#microbiology hashtag#mikrobiologi hashtag#kliniskmikrobiologi hashtag#bacteriology hashtag#antimicrobialresistance hashtag#antimicrobialstewardship hashtag#madeinitaly hashtag#colistin
@ iantobach Many thanks for sharing TP paper. Very good read . Does seem clinical trial design strategy changes every presentation. Anyway all the better this time round , think pre|CISION™ technology asset IP just got more valuable . ( appreciate obviously not yet demonstrated in current SP )
Very pleased our CEO has secured the IP rights be no surprise i wish him to say in post .
Anyway note a few changes to TP investor slides not seen before dated Feb 2024
FYI :
"£33m raise to progress drug pipeline "
" If Phase 2 testing enables commercial sales to start from 2026/27, we calculate a value for AVA6000 alone at 106p rising to 217p on the implementation of Phase 2 testing. "
"A leading UK healthcare company with cutting edge bioscience Avacta has announced an equity raise for up to £26.8m, since increased to £32.5m on strong demand.
The funds raised are to progress the drug development pipeline, primarily for Avacta’s lead clinical asset AVA6000, where the company anticipates a potential start of the expansion cohorts in several orphan diseases in 2H24 followed by the Phase 2 study, consistent with previous guidance. Avacta has also confirmed its intention to divest its Diagnostics division in a manner which maximises benefit for shareholders and to explore a possible NASDAQ listing. Cash at 1 January stood at £16.6m, which was significantly better than consensus expectations and indicates a sharp reduction in the pace of net cash utilisation in 2H23. Nevertheless, given the funding requirement to get AVA6000 into Phase 2 readiness and its importance to the Avacta investment thesis as the company’s lead clinical asset, we believe this is a prudent step."
"Avacta disclosed cash of £16.6m at 1 January 2024, well ahead of consensus expectations of a net debt position of £5.0m at YE23, together with outstanding convertible debt principal of £40.8m, which we expect will convert. That implies net cash utilisation fell from £15.8m in 1H23 to £9.4m in 2H23.
Avacta published a highly positive readout of its Phase 1a data for AVA6000 last December which demonstrated significantly improved safety and tolerability of doxorubicin and included encouraging preliminary clinical signs of anti-tumour activity. There is no meaningful update on that readout from yesterday’s announcement with screening ongoing for a two-weekly dosing study. The dose expansions preceding entry into a Phase 2 trial are expected to be in several orphan indications including soft tissue sarcomas with selection informed by data from the ongoing two and three weekly dose escalation studies.
If Phase 2 testing enables commercial sales to start from 2026/27, we calculate a value for AVA6000 alone at 106p rising to 217p on the implementation of Phase 2 testing. "
Interesting " "Joint Bookrunners") are acting as joint bookrunners in respect of the Placing. Beech Hill Securities, Inc. ("Beech Hill" and, together with the Joint Bookrunners, the "Banks") is acting as US placing agent."
https://www.beechhillsecurities.com/
Not quite what i was expecting anyway guess we start again - still believe value in the assets - hopefully when the dust settles company will make good progress with the science and will attract some serious biotech interest .
At first glance plans seem not to have changed .
Sorry for those of you disappointed , understandable re-action , anyway life goes on - maybe in a few months siituation will be better so happier times ahead .
Hi B2HS2L Link Might need to run it through translation :
http://affyxell.com/bbs/?so_table=news&mode=VIEW&num=38&category=&findType=&findWord=&sort1=&sort2=&page=1
Avacta JV recent update :
"Jeon Seung-ho, CEO of Daewoong Pharmaceutical, "Apicell, Nurturing into a Global Unicorn"
date 2024-01-25 14:14:55
FDA Pre-Clinical Meeting..."100% Achieved"
"2026 IPO Plans... Technology exports are also discussed."
"Apicell Therapeutics expects to enter Phase 1 clinical trials of AFX001 next year if it receives IND approval from the FDA. "
Jeon Seung-ho, CEO of Daewoong Pharmaceutical, was looking for a way to clarify the mechanism of action of mesenchymal stem cell therapy and discovered Abacta, a British biotech that has a similar antibody therapy technology 'Apimer Platform'. Since then, Daewoong Pharmaceutical's next-generation mesenchymal stem cell therapy ('DW-MSC') has verified the technology to inject the Apimer gene and established a joint venture 'Apicell Therapeutics' in 2020. Apicell Therapeutics, which is celebrating its fourth year of existence, is currently preparing for the U.S. Phase 1 clinical trial of its lead pipeline 'AFX001'./Photo=Lee Myung-geun qwe123@
Cell and gene therapy (CGT) is a new modality that global pharmaceutical companies are paying as much attention to as ADCs (antibody drug conjugates). According to the National Institute for Biotechnology Policy, the average annual growth rate of the global CGT market (2021~2027) is expected to reach 44.1%.
Daewoong Pharmaceutical, one of Korea's top five pharmaceutical companies, is also putting a lot of effort into the development of cell and gene therapies. The core base is 'Apicell Therapeutics'. It is a joint venture (joint venture) established by Jeon Seung-ho, CEO of Daewoong Pharmaceutical, in 2020 with British biotech Abacta while leading the open innovation project.
Apicell Therapeutics has the 'Apicell Platform' that combines the technologies of Daewoong Pharmaceutical and Abacta. It is a next-generation cell and gene therapy platform that injects genes into Daewoong Pharmaceutical's mesenchymal stem cell therapy ('DW-MSC'), which is capable of long-term transit culture (cell proliferation), to express 'Affimer', an antibody-like protein of Avacta.
CEO Jeon Seung-ho, who met at Daewoong Pharmaceutical's new building in Samseong-dong, Gangnam-gu, Seoul on the 24th, said, "Therapeutics made with the Apicell platform have the advantages of both stem cell therapy and antibody therapy," and "In preclinical trials, we confirmed the synergy effect (synergy) between Daewoong Pharmaceutical's and Avacta's platforms."
Recently, Apicell Therapeutics completed a pre-clinical trial plan (IND) meeting with the U.S. Food and Drug Administration (FDA) for the clinical entry of its lead pipeline 'AFX001' incorporating this technology. AFX001 is an autoimmune disease treatment that targets CD40L, which is involved in the mutual activation of T and B cells."
CA No conviction- Avacta was one of his best stock picks last month just a charlatan , at least the interviewee got it right good long term hold , science will prevail , future value is in the asset ,ignore the current SP etc .
Thanks Energyshares Yes listen to the experts not forgetting our key man Dr Tap in the USA & also Head Investigator at Leeds Hospital Prof Chris Twleves
https://twitter.com/avacta/status/1735703512695148582
-------
Dr William Tap, Chief, Sarcoma Medical Oncology at Memorial Sloan Kettering Cancer Center, NY also commented:
"These initial clinical data are encouraging and demonstrate that the novel drug delivery mechanism of AVA6000 has the potential to demonstrate single agent activity in patients with solid tumours that express high levels of FAP. The safety data when compared with standard doxorubicin are highly encouraging and demonstrate the power of the pre|CISION? platform to avoid normal tissue effects while concentrating the toxin in the tumor microenvironment."
Good Morning
David Wilson Avacta Chief Commercial Officer | Driving Global IVD Business Growth
liked this : Perhaps opportunity for Avacta Launch Diagnostics .
https://www.bivda.org.uk/Portals/0/documents/External_Affairs/BIVDA%20AMR%20Consensus%20Statement%20Final.pdf?ver=IcdF3HfhVEEjnR-rvH5hiw%3d%3d
https://www.launchdiagnostics.com/product/liofilchem-mic-test-strip-mts/
-----------------------------------
Linkedin
"British In Vitro Diagnostics Association (BIVDA)British In Vitro Diagnostics Association (BIVDA)
5,412 followers5,412 followers
19h • Edited • 19h • Edited •
Follow
📢 Coalition calls for testing to tackle threat of Antimicrobial Resistance
A new coalition of industry and health charities, led by former Health Minister, raise the alarm over missed opportunities to tackle Antimicrobial Resistance in the UK.
Action urgently needed to adopt point of care diagnostics and end years of delay in implementing key recommendations for antimicrobial stewardship.
A cross-sector coalition of health and diagnostics organisations are calling for urgent action to combat the imminent threat of antimicrobial resistance (AMR).
Led by the British In Vitro Diagnostics Association (BIVDA) and the former Health Minister, Maggie Throup MP, who was responsible for the roll out of the COVID-19 vaccine, the coalition is highlighting missed opportunities to use proven diagnostic technology that can help to reduce prescribing of antibiotics when they are not needed.
Supporting the coalition, former Minister for Vaccines and Public Health, Maggie Throup MP said “I am deeply concerned about the slow progress that has been made to support the use of point of care tests as part of the UK’s antimicrobial stewardship efforts. AMR is a tremendous threat, and it is critical that we don’t miss opportunities to slow the progress of resistance. That is why we are calling on the government to prioritise the effective adoption of point of care testing in community and primary care settings.
The pandemic underlined that the government and health system can move quickly to roll-out diagnostics and respond to major health threats – we must act now, with the same urgency, to tackle the problem of AMR.”
Deaths in the UK related to hashtag#AMR are estimated to stand at 12,000 per year, the equivalent of deaths from breast cancer each year, and more deaths than from suicide (approx. 6,500). Ten million people each year are predicted to die globally from AMR by 2050 unless urgent measures are taken.
Coming together to set out a call to action for government and the NHS, the cross-sector coalition has expressed concern over the extended delays to implementing key recommendations on using point-of-care tests to tackle AMR. "